Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-18T23:36:44.268Z Has data issue: false hasContentIssue false

A Systematic Review of State and Manufacturer Physician Payment Disclosure Websites: Implications for Implementation of the Sunshine Act

Published online by Cambridge University Press:  01 January 2021

Extract

Public disclosure of industry payments to physicians is one way to address financial conflicts of interest in medicine. As part of the Patient Protection and Affordable Care Act, the Physician Payment Sunshine Act (PPSA) requires pharmaceutical, medical device, and biologics manufacturers who have at least one product reimbursed by Medicare or Medicaid to disclose payments to physicians and teaching hospitals on a public website starting in 2014. The physician payment data will contain individual physician names, monetary values, and specific products connected to payments.

According to the Final Regulations issued by the Centers for Medicare and Medicaid Services (CMS) in February 2013, the law will make transparent the extent and nature of relationships between physicians, teaching hospitals, and manufacturers.

Type
Independent
Copyright
Copyright © American Society of Law, Medicine and Ethics 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chimonas, S. Rozario, N. M. Rothman, D. J., “Show Us the Money: Lessons in Transparency from State Pharmaceutical Marketing Disclosure Laws,” HSR 45, no. 1 (2010): 98114, at 99; Lo, B., “Commentary: Conflict of Interest Policies: An Opportunity for the Medical Profession to Take the Lead,” Academic Medicine 85, no. 1 (2010): 9–11.Google Scholar
Steinbrook, R. Ross, J. S., “Transparency Reports on Industry Payments to Physicians and Teaching Hospitals,” JAMA 307, no. 10 (2012): 10291030.CrossRefGoogle Scholar
Centers for Medicare and Medicaid Services, “Medicare, Medicaid, Children's Health Insurance Programs: Transparency Reports and Reporting of Physician Ownership or Investment Interests,” Federal Register 78, no. 27 (2013): 9458–9528, at 9458–9459.Google Scholar
Berland, G. K. Elliott, M. N. Morales, L. S. Algazy, J. I. Kravitz, R. L. Broder, M. S. et al., “Health Information on the Internet: Accessibility, Quality and Readability in English and Spanish,” JAMA 285, no. 20 (2001): 26122621, at 2612–2613.CrossRefGoogle Scholar
See Centers for Medicare and Medicaid Services, supra note 3, at 9475; Kim, P. Eng, T. R. Deering, M. J. Maxfield, A., “Published Criteria for Evaluating Health Related Web Sites: Review,” BMJ 318, no. 7184 (1999): 647–649.CrossRefGoogle Scholar
See Centers for Medicare and Medicaid Services, supra note 3, at 9459.Google Scholar
Executive Office of Health and Human Services, State of Massachusetts, “Frequently Asked Questions, Pharmaceutical and Medical Device Manufacturer Code of Conduct,” last modified March 29, 2012, available at <http://www.mass.gov/eohhs/docs/dph/quality/healthcare/pharm-medical-device-conduct-faq.pdf>(last visited April 17, 2014).(last+visited+April+17,+2014).>Google Scholar
“Lilly Physician Payment Registry,” available at <http://206.246.145.152/>(last visited April 17, 2014).(last+visited+April+17,+2014).>Google Scholar
“Merck Ethics and Transparency,” available at <http://www.merckresponsibility.com/focus-areas/ethics-transparency/transparency-disclosures/payments-to-u-s-based-healthcare-professionals/>(last visited April 23, 2014).(last+visited+April+23,+2014).>Google Scholar
Cephalon, , “Relationships with Healthcare Professionals,” available at <http://www.cephalon.com/our-responsibility/relationships-with-healthcare-professionals.html>(last visited October 22, 2012). N.B. Cephalon has since been acquired by Teva Pharmaceuticals. The above link is no longer active. Teva Pharmaceuticals USA offers a new link at <http://www.tevausa.com/Relationships.aspx>(last visited April 23, 2014).(last+visited+October+22,+2012).+N.B.+Cephalon+has+since+been+acquired+by+Teva+Pharmaceuticals.+The+above+link+is+no+longer+active.+Teva+Pharmaceuticals+USA+offers+a+new+link+at+(last+visited+April+23,+2014).>Google Scholar
Stryker, , “Meet Our Consultants,” available at <http://www.stryker.com/meetourconsultants/consultants/consultants.php>(last visited April 17, 2014).(last+visited+April+17,+2014).>Google Scholar
DePuy Synthes, “Physician and Institution Pymt,” available at <http://www.depuy.com/about-depuy/depuy-divisions/depuy-orthopaedics/find-surgeon>(last accessed October 22, 2012).(last+accessed+October+22,+2012).>Google Scholar
Glaxosmithkline, “Glaxosmithkline Frequently Asked Questions,” available at <http://us.gsk.com/html/responsibility/speakers-advisors-faqs.html#11>(last accessed October 22, 2012). N.B. In December 2013, GSK announced that it will stop paying U.S. health care professionals outside of the company to speak. The above link is no longer active and has been replaced by <http://fortherecord.payments.us.gsk.com/transparency.html>(last visited April 23, 2014).(last+accessed+October+22,+2012).+N.B.+In+December+2013,+GSK+announced+that+it+will+stop+paying+U.S.+health+care+professionals+outside+of+the+company+to+speak.+The+above+link+is+no+longer+active+and+has+been+replaced+by+(last+visited+April+23,+2014).>Google Scholar
Donelan, K. Rogers, R. S. Eisenhauer, A. Mort, E. Agnihotri, A. K., “Consumer Comprehension of Surgeon Performance Data for Coronary Bypass Procedures,” Annals of Thoracic Surgery 91, no. 5 (2011): 14001406.CrossRefGoogle Scholar
See Centers for Medicare and Medicaid Services, supra note 3, at 9481.Google Scholar
Id, at 9474.Google Scholar
Rodwin, M. A., “Physicians' Conflicts of Interest: The Limitations of Disclosure,” New England Journal of Medicine 321, no. 20 (1989): 14051408, at 1405.CrossRefGoogle Scholar
See Centers for Medicare and Medicaid Services, supra note 3, at 9503.Google Scholar
Rosenthal, M. B. Mello, M. M., “Sunlight as Disinfectant –New Rules on Disclosure of Industry Payments to Physicians,” New England Journal of Medicine 368, no. 22 (2013): 20522054, at 2053.CrossRefGoogle Scholar
See Center for Medicare and Medicaid Services, supra note 3, at 9503–9504.Google Scholar
Brennan, T. A. Rothman, D. J. Blank, L. Blumenthal, D. Chimonas, S. C. Cohen, J. J. et al., “Health Industry Practices That Create Conflicts of Interest,” JAMA 295, no. 4 (2006): 429433; IOM (Institute of Medicine), Lo, B. Field, M. J., eds., Conflict of Interest in Medical Research, Education, and Practice (Washington, D.C.: The National Academies Press, 2009): At Ch. 6–7.CrossRefGoogle Scholar
Wazana, A., “Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?” JAMA 283, no. 3 (2000): 373380.CrossRefGoogle Scholar
See Lo, Field, , supra note 19; Association of American Medical Colleges (AAMC), In the Interest of Patients: Recommendations of Physician Financial Relationships and Clinical Decision Making (Washington, D.C.: AAMC, 2010).Google Scholar
See Centers for Medicare and Medicaid Services, supra note 3, at 9459.Google Scholar
MMIS, Inc., “Sunshine Act: More Than 50% of Physicians Unprepared,” MMIS Media Center, February 4, 2013, available at <http://www.mmis-inc.com/pressrelease_3rdphysiciansurvey>(last visited April 17, 2014).(last+visited+April+17,+2014).>Google Scholar
Agrawal, S. Brennan, N. Budetti, P., “The Sunshine Act – Effects on Physicians,” New England Journal of Medicine 368, no. 22 (2013): 20542057.CrossRefGoogle Scholar
Licurse, A. Barber, E. Joffe, S. Gross, C., “The Impact of Disclosing Financial Ties in Research and Clinical Care,” Archives of Internal Medicine 170, no. 8 (2010): 675682.CrossRefGoogle Scholar
Cain, D. M. Loewenstein, G. Moore, D. A., “When Sunlight Fails to Disinfect: Understanding the Perverse Effects of Disclosing Conflicts of Interest,” Journal of Consumer Research 37, no. 5 (2011): 836857; Loewenstein, G. Sah, S. Cain, D. M., “The Unintended Consequences of Conflict of Interest Disclosure,” JAMA 307, no. 7 (2012): 669–670; Hampson, L. A. Agrawal, M. Joffe, S. Gross, C. P. Verter, J. Emanuel, E. J., “Patients' Views on Financial Conflicts of Interest in Cancer Research Trials,” New England Journal of Medicine 355, no. 22 (2006): 2330–2337; Weinfurt, K. P. Hall, M. A. King, N. M. P. Friedman, J. Y. Schulman, K. A. Sugarman, J., “Disclosure of Financial Relationship to Participants in Clinical Research,” New England Journal of Medicine 361, no. 9 (2009): 916–921.CrossRefGoogle Scholar
Pham-Kanter, G. Alexander, G. C. Nair, K., “Effect of Physician Payment Disclosure Laws on Prescribing,” Archives of Internal Medicine 172, no. 10 (2012): 819821.CrossRefGoogle Scholar